Replies to post #104010 on Biotech Values

[genisi]

I think that MRK is trying to say that even though prior nulls were excluded from RESPOND-2 study, since 25% of patients in the trial had < 1 log reduction in viral load at week 4 while in the lead, they might be considered nulls. Still, I don't think nulls will be included in boceprevir's label in opposed to telaprevir.